Claims for Patent: 7,510,710

Summary for Patent: 7,510,710

Title:	Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
Abstract:	Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and/or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and/or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.
Inventor(s):	Newell; Martha Karen (Colorado Springs, CO), Newell; Evan (Toronto, CA), Villobos-Menvey; Elizabeth (Monument, CO)
Assignee:	The Regents of the University of Colorado (Denver, CO)
Application Number:	11/031,109
Patent Claims:	1. A composition, comprising: a therapeutically acceptable combination, suitable for administration to a patient, of an isolated fatty acid metabolism inhibitor, wherein the isolated fatty acid metabolism inhibitor is etomoxir, or a pharmacologically acceptable salt thereof and an isolated glucose metabolism inhibitor, wherein the isolated glucose metabolism inhibitor is a 2-deoxy-D-glucose compound. 2. The composition of claim 1, further comprising a colloidal dispersion system. 3. The composition of claim 2 wherein the colloidal dispersion system is a liposome. 4. The composition of claim 1 further comprising a pharmaceutically acceptable carrier. 5. The composition of claim 4 further comprising one or more chemotherapeutic agents. 6. The composition of claim 5 wherein one or more of the chemotherapeutic agents is selected from the group consisting of methotrexate, trimetrexate, adriamycin, taxotere, doxorubicin, 5-flurouracil, vincristine, vinblastine, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, toremifene, letrozole, trastuzumab, megestrol, tamoxifen, paclitaxel, docetaxel, capecitabine, and goserelin acetate.

Details for Patent 7,510,710

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-01-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-01-08
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2024-01-08